Post

New research · Endocrinology
Functional & integrative genomics · 22h
AI / informaticsFunctional & integrative genomics · 2026

ANGPTL4 in gestational diabetes: a diagnostic biomarker linked to placental senescence.

Yu-Feng He, Hui Chen, Chuan-Meng Zhang … Shu-Guang Zhou
Read paper
EndocrinologyAI / informatics

ANGPTL4 is elevated in first-trimester plasma of women who later develop gestational diabetes.

ANGPTL4 in gestational diabetes: a diagnostic biomarker linked to placental senescence.

Yu-Feng He et al. · Functional & integrative genomics · 2026
Background

Current diagnostic methods for Gestational Diabetes Mellitus (GDM) inadequately reflect early placental pathophysiology.

Methods

In parallel, a prospective nested case-control study (30 GDM cases and 30 controls) was conducted, with peripheral blood collected in the first trimester, second trimester, and at delivery.

n = 30 controls
P_adj = 0.038
Results
early pregnancy ANGPTL4 levels were higher in women who developed gestational diabetes
n = 30 controls
More results

The classification model integrating ANGPTL4 and DST demonstrated favorable retrospective discriminatory performance (training set AUC = 0.95; validation set AUC = 0.87).

Cell communication analysis predicted potential ligand-receptor interactions between ANGPTL4 and ITGA5/ITGB1/SDC4 in EVTs.

More results

DE-SRGs in GDM placentas were highly enriched in lipid metabolism pathways, aligning with ANGPTL4's known function.

These correlative findings generate testable hypotheses linking ANGPTL4‑mediated signaling to placental senescence.

“
Conclusion

ANGPTL4 emerges as a candidate biomarker whose clinical potential warrants further evaluation in prospective cohorts.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
OR 18.90
far higher odds of fatty-liver inflammation with scarring at the top blood-marker level
Review
30-37%
SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
0.5 %
only 0.5% of blood sugar tests after birth found lasting high blood sugar
Cohort Study
HR 3.05
a high liver risk score means a threefold higher risk of youth type 2 diabetes
Study
HR 1.72
GLP-1 agonists had a 72% greater risk of non-scarring hair loss than DPP-4 inhibitors
Cohort Study
HR 1.095
a higher triglyceride to HDL cholesterol ratio means a higher risk of new diabetes
Case-control
aHR 2.73
BRCA2 gene changes meant a higher risk of cancer getting worse or death